http://www.cnr.it/ontology/cnr/individuo/prodotto/ID239277
Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? (Articolo in rivista)
- Type
- Label
- Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? (Articolo in rivista) (literal)
- Anno
- 2013-01-01T00:00:00+01:00 (literal)
- Alternative label
Iole Cucinotto,1
Lucia Fiorillo,1
Simona Gualtieri,1
Mariamena Arbitrio,2
Domenico
Ciliberto,1
Nicoletta Staropoli,1
Anna Grimaldi,3
Amalia Luce,3
Pierfrancesco Tassone,1
Michele Caraglia,3
and Pierosandro Tagliaferri1 (2013)
Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?
in Journal of Drug Delivery (Online)
(literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
- Iole Cucinotto,1
Lucia Fiorillo,1
Simona Gualtieri,1
Mariamena Arbitrio,2
Domenico
Ciliberto,1
Nicoletta Staropoli,1
Anna Grimaldi,3
Amalia Luce,3
Pierfrancesco Tassone,1
Michele Caraglia,3
and Pierosandro Tagliaferri1 (literal)
- Pagina inizio
- Pagina fine
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
- Rivista
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
- Note
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
- 1
Medical Oncology Unit, Department of Experimental and Clinical Medicine, University \"Magna Graecia\" of Catanzaro
and \"Tommaso Campanella\" Cancer Center, Campus Salvatore Venuta, Viale Europa, 88100 Catanzaro, Italy
2
Institute of Neurological Science (ISN-CNR), UOS of Pharmacology, Roccelletta di Borgia, 88021 Catanzaro, Italy
3
Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, 80138 Naples, Italy (literal)
- Titolo
- Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? (literal)
- Abstract
- Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer. A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment. This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms. (literal)
- Prodotto di
- Autore CNR
Incoming links:
- Prodotto
- Autore CNR di
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi